LVIVO-TaVec400 product

BIOLOGICAL2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Multiple Myeloma (MM)Progressive Multiple Sclerosis (PMS)Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)Relapsed/Refractory Myasthenia Gravis(r/r MS)Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

Early Phase 1

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

Not yet recruitingNCT07399444

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma (MM)

Start: 2026-01-10End: 2030-05-10Target: 38Updated: 2026-02-10

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

Not yet recruitingNCT07583030

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyProgressive Multiple Sclerosis (PMS), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Relapsed/Refractory Myasthenia Gravis(r/r MS) +1

Start: 2026-04-20End: 2041-09-20Target: 44Updated: 2026-05-13